3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Status
Recruiting
3
Completed
3
Active not recruiting
3
Terminated
1
Enrolling by invitation
1
Available
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Lymphoid
3
Conditions
Lymphoma, Mantle-Cell
2
Recurrence
1
Lymphoma, B-Cell
1
Interventions
pembrolizumab
247
Nivolumab
144
Cyclophosphamide
137
Cisplatin
137
Paclitaxel
115
Carboplatin
111
Gemcitabine
100
Radiotherapy
86
Dexamethasone
84
Docetaxel
79
Ipilimumab
70
atezolizumab
68
Doxorubicin
63
Fluorouracil
60
Blood Specimen Collection
60
Bevacizumab
59
Etoposide
55
fludarabine
54
Rituximab
54
Oxaliplatin
52
Prednisone
51
Lenalidomide
51
Surveys and Questionnaires
50
Cetuximab
47
Standard of Care
46
Capecitabine
46
Radiosurgery
44
Magnetic Resonance Spectroscopy
44
lenvatinib
43
durvalumab
43
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Completed
×
brexucabtagene autoleucel
×
1 year
×
Clear all
NCT02625480
2026-04-09
ZUMA-4
Gilead Sciences
Phase 1/2
Completed
95 enrolled
NCT02601313
2026-03-18
ZUMA-2
Gilead Sciences
Phase 2
Completed
105 enrolled
33 charts
1 FDA
NCT04880434
2025-11-17
ZUMA-2
Gilead Sciences
Phase 2
Completed
95 enrolled